Ir para o conteúdo principal

Sensei Biotherapeutics (NYSE: SNSE) — Perfil da empresa, notícias e dados financeiros

Logo de Sensei Biotherapeutics
SNSE Sensei Biotherapeutics
Sensei Biotherapeutics primary media
Perfil da empresa

Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:SNSE) is a biopharmaceutical company focused on the development of next-generation immunotherapies for cancer and infectious diseases. The company's work revolves around its proprietary ImmunoPhage™ platform and its novel monoclonal antibody and T-cell receptor discovery platform, aimed at tailoring treatments to harness the body's immune system more effectively. Their pipeline includes multiple projects in various stages of research and clinical development, designed to achieve better outcomes for patients with unmet medical needs. Sensei Biotherapeutics is on a mission to transform cancer treatment paradigms and improve patient lives through groundbreaking scientific innovation.

Resumo

Public USParticipação acionária
1999Ano de fundação
27Funcionários
Rockville, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Rockville, US

Produtos e/ou serviços de Sensei Biotherapeutics

  • Immuno-oncology therapeutics harnessing the immune system to fight cancer, focusing on novel treatments for various tumor types.
  • VISTA checkpoint inhibitors targeting the V-set immunoregulatory domain to augment cancer immunotherapy efficacy.
  • Precision medicine approach, using genomic data to tailor unique treatment strategies for cancer patients.
  • Research on bacteriophage-based vaccines aimed at stimulating the immune system against cancer.
  • Pipeline of monoclonal antibodies designed for specific tumor-associated antigens, improving targeted therapy options.
  • Collaborative research partnerships with academic institutions and biotech firms to speed up the development of innovative cancer treatments.

equipe executiva do Sensei Biotherapeutics

  • Mr. Christopher W. Gerry J.D.President, General Counsel & Secretary
  • Mr. Josiah CraverSenior VP of Finance, Principal Financial Officer & Principal Accounting Officer
  • Ms. Lora PikeVice President of Investor Relations & Communications

Principais indicadores financeiros

Resultados divulgados pela Sensei Biotherapeutics, em USD.

Receita e lucro anuais da Sensei Biotherapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-22,3 mi-21,1 mi
0-31,7 mi-30,2 mi
0-37,1 mi-34,1 mi
0-50,2 mi-48,8 mi